Disturbances of glucose metabolism accompanied by insulin resistance are pro-inflammatory conditions which may accelerate atherosclerosis. Diabetic populations are at high cardiovascular risk and strict control of lipoprotein concentrations is recommended. Several recent studies showed the efficacy of statins on primary and secondary prevention of cardiovascular events in diabetic populations. The goal of 100 mg/dL for LDL-cholesterol may be too elevated for subjects at very high risk for whom a target of 70 mg/dl has been suggested. High statin doses may be necessary, which increases its adverse effects. Given that statin monotherapy may be insufficient for the desirable reduction in LDL levels, a combination of lipid-lowering agents has become frequent in clinical practice. In particular, statin and ezetimibe combination has been shown to be very effective in reducing total and LDL cholesterol levels.